306 related articles for article (PubMed ID: 32071913)
1. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.
Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; López López C; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RS
Liver Cancer; 2020 Jan; 9(1):93-104. PubMed ID: 32071913
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
3. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib.
Chen YY; Wang CC; Liu YW; Li WF; Chen YH
PeerJ; 2020; 8():e10382. PubMed ID: 33240675
[TBL] [Abstract][Full Text] [Related]
5. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.
Vogel A; Frenette C; Sung M; Daniele B; Baron A; Chan SL; Blanc JF; Tamai T; Ren M; Lim HJ; Palmer DH; Takami Y; Kudo M
Liver Cancer; 2021 Sep; 10(5):510-521. PubMed ID: 34721512
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Vogel A; Tovoli F; Ueshima K; Aikata H; López CL; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Tamai T; Saito K; Dutcus CE; Lencioni R
J Hepatol; 2023 Jan; 78(1):133-141. PubMed ID: 36341767
[TBL] [Abstract][Full Text] [Related]
7. Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study.
Tajiri K; Tokimitsu Y; Kawai K; Motofuji Y; Shinno E; Kashii Y; Muraishi N; Murayama A; Hayashi Y; Minemura M; Takahara T; Shimizu Y; Yasuda I
Anticancer Res; 2022 Dec; 42(12):6007-6018. PubMed ID: 36456142
[TBL] [Abstract][Full Text] [Related]
8. Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
Fukushima T; Morimoto M; Ueno M; Kubota K; Uojima H; Hidaka H; Chuma M; Numata K; Tsuruya K; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Yamamoto K; Tanaka K; Maeda S
JGH Open; 2022 Jan; 6(1):29-35. PubMed ID: 35071785
[TBL] [Abstract][Full Text] [Related]
9. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
10. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.
Choi NR; Kim JY; Hong JH; Hur MH; Cho H; Park MK; Kim J; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
BMC Gastroenterol; 2022 Mar; 22(1):135. PubMed ID: 35337274
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.
Lee SW; Yang SS; Lien HC; Peng YC; Ko CW; Lee TY
J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268535
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
15. Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Piscaglia F; Ikeda K; Cheng AL; Kudo M; Ikeda M; Breder V; Ryoo BY; Mody K; Ren M; Ramji Z; Sung MW
Cancer; 2024 Apr; 130(8):1281-1291. PubMed ID: 38261521
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Wang S; Wang Y; Yu J; Wu H; Zhou Y
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428618
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
Casadei-Gardini A; Scartozzi M; Tada T; Yoo C; Shimose S; Masi G; Lonardi S; Frassineti LG; Nicola S; Piscaglia F; Kumada T; Kim HD; Koga H; Vivaldi C; Soldà C; Hiraoka A; Bang Y; Atsukawa M; Torimura T; Tsuj K; Itobayashi E; Toyoda H; Fukunishi S; Rimassa L; Rimini M; Cascinu S; Cucchetti A
Liver Int; 2021 Jun; 41(6):1389-1397. PubMed ID: 33547848
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
Kim JJ; McFarlane T; Tully S; Wong WWL
Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function.
Huynh J; Cho MT; Kim EJ; Ren M; Ramji Z; Vogel A
Ther Adv Med Oncol; 2022; 14():17588359221116608. PubMed ID: 36051472
[TBL] [Abstract][Full Text] [Related]
20. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
